These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evaluation of a potent inhibitor of subprimate and primate renins. Wood JM, Mah SC, Baum HP, de Gasparo M, Cumin F, Rüeger H, Nussberger J. J Pharmacol Exp Ther; 1990 May; 253(2):513-7. PubMed ID: 2110974 [Abstract] [Full Text] [Related]
4. Statine-containing renin inhibitor. Dissociation of blood pressure lowering and renin inhibition in sodium-deficient dogs. Blaine EH, Schorn TW, Boger J. Hypertension; 1984 May; 6(2 Pt 2):I111-8. PubMed ID: 6373590 [Abstract] [Full Text] [Related]
5. H-77: a potent new renin inhibitor. In vitro and in vivo studies. Szelke M, Leckie BJ, Tree M, Brown A, Grant J, Hallett A, Hughes M, Jones DM, Lever AF. Hypertension; 1982 May; 4(3 Pt 2):59-69. PubMed ID: 7040240 [Abstract] [Full Text] [Related]
6. Non-specific inhibition of pressor agents in vivo by the renin inhibitor pepstatin A. Oldham AA, Arnstein MJ, Major JS, Clough DP. J Hypertens; 1984 Apr; 2(2):157-61. PubMed ID: 6398334 [Abstract] [Full Text] [Related]
7. Effects of the renin inhibitor H77 on angiotensin II, arterial pressure and cardiac function in conscious dogs: comparison with captopril. Tree M, MacArthur K, Inglis G, Leckie B, Lever AF, Morton JJ, Szelke M. J Hypertens Suppl; 1989 Apr; 7(2):S51-5. PubMed ID: 2666615 [Abstract] [Full Text] [Related]
8. CGP 38 560: orally active, low-molecular-weight renin inhibitor with high potency and specificity. Wood JM, Criscione L, de Gasparo M, Bühlmayer P, Rüeger H, Stanton JL, Jupp RA, Kay J. J Cardiovasc Pharmacol; 1989 Aug; 14(2):221-6. PubMed ID: 2476594 [Abstract] [Full Text] [Related]
9. Inhibition of dog renin activity by pepstatin A. Miyazaki M, Komori T, Okunishi H, Toda N. Jpn Circ J; 1979 Sep; 43(9):818-23. PubMed ID: 501901 [Abstract] [Full Text] [Related]
14. [In vitro and in vivo inhibition of renin by a thiazolylalanyl cyclostatine derivative]. Muneta S. Nihon Jinzo Gakkai Shi; 1989 Aug; 31(8):865. PubMed ID: 2512401 [Abstract] [Full Text] [Related]
16. A highly potent and long-acting oral inhibitor of human renin. Hiwada K, Kokubu T, Murakami E, Muneta S, Morisawa Y, Yabe Y, Koike H, Iijima Y. Hypertension; 1988 Jun; 11(6 Pt 2):708-12. PubMed ID: 3134306 [Abstract] [Full Text] [Related]
17. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, Weitz D, Bohn DL, Wenger HC, Vassil TC, Stone CA. J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322 [Abstract] [Full Text] [Related]
18. New inhibitors of human renin tested in vitro and in vivo in the anaesthetized baboon. Tree M, Atrash B, Donovan B, Gamble J, Hallett A, Hughes M, Jones DM, Leckie B, Lever AF, Morton JJ. J Hypertens; 1983 Dec; 1(4):399-403. PubMed ID: 6398331 [Abstract] [Full Text] [Related]
19. Renin inhibitors: their use in understanding the role of angiotensin II as a pressor hormone. Tree M, Szelke M, Leckie B, Atrash B, Donovan B, Hallett A, Jones DM, Lever AF, Morton JJ, Sueiras-Diaz J. J Cardiovasc Pharmacol; 1985 Dec; 7 Suppl 4():S49-52. PubMed ID: 2412013 [Abstract] [Full Text] [Related]